Clinical Trials

3,680 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT06385080 2026-06-05

OrigAMI-4

Phase 1/2 Recruiting

287 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07007559 2026-06-05

ASPEN-09-03

120 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07061977 2026-06-05

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

336 enrolled

Locally Advanced Cervical Adenocarcinoma

NCT07063745 2026-06-05

MountainTAP-29

Phase 2/3 Recruiting

590 enrolled

Lung Neoplasms

NCT07198074 2026-06-05

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

255 enrolled

Endometrial Neoplasms

NCT04729387 2026-06-04

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3 Terminated

358 enrolled 19 charts

Ovarian Neoplasms

NCT06694454 2026-06-04

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Recruiting

60 enrolled

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT06856213 2026-06-04

ERBIOTAX

Phase 2 Not yet recruiting

65 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07234877 2026-06-04

Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets

158 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07518147 2026-06-04

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

438 enrolled

Stomach Neoplasms

NCT02446600 2026-06-03

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03587311 2026-06-03

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

96 enrolled

Fallopian Tube Endometrioid Adenocarcinoma

NCT04267848 2026-06-03

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

1,210 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05256225 2026-06-03

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

360 enrolled

Neoplasms, Endometrial Neoplasms

NCT06096844 2026-06-03

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

304 enrolled

Lung Neoplasms

NCT06194448 2026-06-03

NEOLA

76 enrolled

Lung Neoplasms

NCT06952504 2026-06-03

TroFuse-033

1,123 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT07564141 2026-06-03

RAINFOL™-07

688 enrolled

Ovarian Neoplasms

NCT00951496 2026-06-02

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 3 Completed

1,560 enrolled 19 charts

Brenner Tumor

NCT01196390 2026-06-02

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Phase 3 Completed

203 enrolled 22 charts

Phase 1/2 Active not recruiting

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT04083599 2026-06-02

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

350 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT04527991 2026-06-02

TROPiCS-04

Phase 3 Completed

711 enrolled 25 charts

Genitourinary

Locally Advanced or Metastatic Unresectable Urothelial Cancer

NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

2,900 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05739981 2026-06-02

MRD

Phase 1/2 Recruiting

30 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05751668 2026-06-02

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)

Phase 2 Suspended

98 enrolled

Breast Neoplasms

NCT06018337 2026-06-02

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

541 enrolled

Breast Neoplasms

NCT06524544 2026-06-02

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

320 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06619236 2026-06-02

RAINFOL-02

448 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06914011 2026-06-02

MRD2START

172 enrolled

Esophageal Neoplasms

NCT06915025 2026-06-02

OVATION-3

500 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07604766 2026-06-02

RAINFOL-02

82 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07621601 2026-06-02

A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

494 enrolled

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis

NCT02379416 2026-06-01

Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

Phase 1 Completed

47 enrolled

Tumor-Agnostic

Neoplasms

NCT04269200 2026-06-01

DUO-E

805 enrolled 18 charts 1 FDA

Endometrial Neoplasms

NCT04736173 2026-06-01

ARC-10

169 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04858269 2026-06-01

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

DermatologicGynecologicHead & NeckSarcoma

32 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT05039801 2026-06-01

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Phase 1 Recruiting

54 enrolled

Squamous Cell Carcinoma of Head and Neck, Chondrosarcoma, Melanoma, Ovarian Neoplasms, Endometrial Neoplasms

NCT05633667 2026-06-01

VELOCITY-Lung

192 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06422143 2026-06-01

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

851 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06788912 2026-06-01

MK-3475-01E

60 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT06966700 2026-06-01

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

2,400 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07060807 2026-06-01

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

1,000 enrolled

Breast Neoplasms

NCT07214779 2026-06-01

MAESTRA 2

466 enrolled

Ovarian Neoplasms

NCT07216703 2026-06-01

TroFuse-036

1,023 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT00433511 2026-05-29

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

4,994 enrolled 11 charts

Breast Adenocarcinoma

NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

349 enrolled 11 charts

GynecologicSarcoma

Endometrial Adenocarcinoma

NCT01081262 2026-05-29

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

50 enrolled 13 charts